KOL Insight: Melanoma [2020]

Therapy Trends KOL Insight: Melanoma [2020]

Why do KOLs foresee an expansion of Merck's anti-PD-1 therapy Keytruda in the adjuvant setting? Could Eli Lilly/Innovent Biologics' sintilimab/ipilimumab biosimilar combination threaten BMS' Opdivo/Yervoy domination of advanced melanoma treatment? And why do KOLs believe Iovance Biotherapeutics' pipeline lifileucel has the potential to change practice for patients' refractory to multiple-lines of therapy? US and European KOLs critically assess the prospects of launched and pipeline therapies.

Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.

I want an edge. Let's talk

Key questions answered

Why do oncologists suggest the anti-PD1/CTLA4 blockade could be practice changing in the neoadjuvant setting?
Why are experts underwhelmed with Roche's triple combination of Tecentriq with Cotellic/Zelboraf?
Why do KOLs believe Nektar/BMS' late stage bempegaldesleukin/nivolumab combination could be a potential competitor to Opdivo/Yervoy?
How and where do oncologists see potential value for Idera's PIII tilsotolimod/Yervoy combination?

Examples of Therapies Covered

•

Yervoy

•

Opdivo

•

Keytruda

•

IBI310

•

Tafinlar/Mekinist

•

Zelboraf/Cotellic

•

Relatlimab

•

Spartalizumab

•

Tilsotolimod

•

Tyvyt

Partial List of Participating KOLs

Oncology Specialist, MedStar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC.
Professor of Medicine (Hematology/Oncology), Roswell Park Cancer Institute, 915 CSC Building, Elm and Carlton Streets, Buffalo, NY.
Oncology Specialist, Professor, Moffitt Cancer Center and University of South Florida Morsani College of Medicine, Tampa, FL.
Professor & Chief Scientific Officer, Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands.
Professor of Medicine, Head of the Dermatology Unit at the Gustave Roussy Cancer Centre, Villejuif-Paris, France.
Professor of Medicine, University of Zurich, Vice-Chairman, Department of Dermatology, University Hospital of Zürich. Switzerland.

Contact us for a full list of KOLs

We engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.

Our-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.

Our reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.

Continuous Monitoring Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.	Boardroom Ready Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Future Driven Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.	Deep Dive Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.

Contact Us
First Name*
Last Name*
Email*
Job Title*
Phone*
Company Name *
Country Name *
Company
Job Function
Clean_Company
World_Region
FW_Sub_Type
ProductName
Brand_Name
Account Owner
Account_Type
Lead_Type
Product_Code
UID

Contact Us

KOL Insight: Melanoma [2020]

Browse by